Recombinant Human Erythropoietin Receptor
BackgroundThe erythropoietin receptor is a transmembrane protein belonging to the member of the cytokine receptor family. The receptor is tyrosine phosphorylated upon binding by erythropoietin and associates with and activates the tyrosine kinase, JAK2, which activates different intracellular pathways including: Ras/MAP kinase, phosphatidylinositol 3-kinase and STAT transcription factors. EPO-R transmits signals important for both proliferation and differentiation along the erythroid lineage.1 Defects in the erythropoietin receptor may produce erythroleukemia and familial erythrocytosis. Protein DetailsPurity >90% by SDS-PAGE and analyzed by silver stain. Endotoxin Level <0.1 ng per 1 µg as determined by the LAL method Biological Activity The biological activity of Human Epo R was determined by its ability to inhibit Epodependent proliferation of TF1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The expected ED<sub>50</sub> is 1 - 4 ng/ml in the presence of 0.2 U/ml of
rhEpo. Fusion Protein Tag Fc Fusion Protein Protein Accession No. Amino Acid Sequence apppnlpdpk feskaallaa rgpeellcft erledlvcfw eeaasagvgp gnysfsyqle depwklcrlh qaptargavr fwcslptadt ssfvplelrv taasgapryh rvihinevvl ldapvglvar ladesghvvl rwlpppetpm tshiryevdv sagngagsvq rveilegrte cvlsnlrgrt rytfavrarm aepsfggfws awsepvsllt psdldpkscd kthtcppcpa pellggpsvf lfppkpkdtl misrtpevtc vvvdvshedp evkfnwyvdg vevhnaktkp reeqynstyr vvsvltvlhq dwlngkeykc kvsnkalpap iektiskakg qprepqvytl ppsrdeltkn qvsltclvkg fypsdiavew esngqpenny kttppvldsd gsfflysklt vdksrwqqgn vfscsvmhea lhnhytqksl slspgk State of Matter Lyophilized Predicted Molecular Mass The predicted molecular weight of Recombinant Human Epo R is Mr 51.4 kDa. However, the actual molecular weight as observed by migration on SDS-PAGE is Mr 55-60 kDa. Predicted Molecular Mass 51.4 Formulation This recombinant protein was 0.2 µm filtered and lyophilized from PBS with 0.1 mM EDTA and 0.05 % CHAPS, pH 7.2. Storage and Stability This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions. Country of Origin USA Shipping Next Day Ambient NCBI Gene Bank Leinco Protein AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Using Recombinant Human Erythropoietin Receptor (EPO-R) in research applications is essential for studying erythropoietin (EPO) signaling, receptor-ligand interactions, and downstream biological effects in hematopoiesis, tissue protection, and disease models. Key scientific applications and advantages:
Best practices:
Summary of scientific rationale: Employing recombinant EPO-R in research provides a controlled, reproducible system to dissect EPO signaling, model disease mechanisms, and evaluate therapeutic interventions across hematopoietic and non-hematopoietic contexts. This is critical for advancing understanding of erythropoiesis, tissue protection, and receptor pharmacology. Yes, you can use recombinant human erythropoietin receptor (EpoR) as a standard for quantification or calibration in ELISA assays, provided the assay is designed to detect EpoR and the recombinant protein is compatible with your assay format. Key considerations and supporting details:
Summary Table: Use of Recombinant EpoR as ELISA Standard
Important: Do not use recombinant EpoR as a standard in EPO quantification assays, as these require recombinant EPO, not its receptor. If your ELISA is for EpoR detection, recombinant human EpoR is appropriate and widely used as a standard for quantification and calibration. Recombinant Human Erythropoietin Applications in Published ResearchRecombinant human erythropoietin (rHuEPO) has been validated for a diverse range of clinical and research applications across hematopoietic and non-hematopoietic domains. Primary Hematopoietic ApplicationsThe most established clinical applications involve treating various forms of anemia. rHuEPO is approved for anemia associated with chronic kidney disease, including both dialysis-dependent and non-dialysis patients. It is also validated for treating chemotherapy-induced anemia in patients with nonmyeloid malignancies, and for managing anemia in HIV-infected patients receiving zidovudine therapy. Additionally, rHuEPO has been validated for reducing allogeneic blood transfusion requirements in patients undergoing elective orthopedic surgery. The mechanism underlying these applications involves rHuEPO's ability to promote erythropoiesis by enhancing survival of erythroid progenitor cells and primitive erythrocytes, thereby increasing red blood cell production and hemoglobin concentration. Emerging Non-Hematopoietic ApplicationsBeyond traditional hematologic uses, rHuEPO has demonstrated therapeutic potential in multiple organ systems. Research has validated its application in neuroprotection and neuroregenerative therapy, with documented benefits in ischemic stroke and chronic schizophrenia shown in double-blind placebo-controlled clinical studies. Preclinical findings suggest therapeutic potential for neurological conditions including head trauma and epilepsy. rHuEPO exhibits cytoprotective properties through anti-oxidative, anti-apoptotic, and anti-inflammatory mechanisms. These protective effects have led to investigation in cardiovascular disease, hepatobiliary surgery, and general surgery applications. The protein also shows promise in treating retinal diseases and other conditions affecting the nervous system. Research and Bioactivity ValidationIn laboratory settings, rHuEPO has been validated for bioactivity assessment and Western blot control applications, with bioactivity measured through its ability to inhibit erythropoietin-dependent cell proliferation in standardized assays. Engineered VariantsRecent research has validated immunogenicity-reduced variants of rHuEPO designed through computational protein engineering, which maintain biological function while reducing immune responses in specific patient populations. Reconstitution ProtocolReconstitute the lyophilized recombinant human erythropoietin receptor (EPOR) protein by first centrifuging the vial briefly prior to opening to bring contents to the bottom. Reconstitute the protein in sterile distilled water to a concentration of 0.1–1.0 mg/mL. For optimal results, allow the vial and reconstitution buffer to equilibrate to room temperature before adding the buffer, then permit 15–30 minutes of gentle agitation for complete dissolution. If flakes persist, continue mixing for approximately 2 hours at room temperature. Buffer and Formulation ConsiderationsThe specific reconstitution buffer depends on your experimental requirements and the formulation type: Standard formulations typically contain trehalose and carrier proteins (such as bovine serum albumin) and should be reconstituted in sterile PBS containing at least 0.1% human or bovine serum albumin. Carrier-free formulations are reconstituted in sterile PBS without additional carrier proteins. Alternative approach involves reconstituting in sterile distilled water alone, with optional addition of 5–50% glycerol (final concentration) to enhance stability. Avoid vigorous vortexing or mixing of protein solutions, as this can denature the protein and reduce biological activity. Storage and StabilityAfter reconstitution, aliquot the protein into working portions and store at ≤–20°C for long-term stability. Reconstituted protein solutions can be maintained at 4–8°C for 1–7 days, depending on formulation. Aliquots stored at –20°C remain stable for approximately 3 months. Critical consideration: Avoid repeated freeze-thaw cycles, as these significantly compromise protein integrity and biological function. Use a manual defrost freezer and plan your aliquoting strategy accordingly to minimize thawing events. Pre-Experimental DilutionsFor cell culture experiments requiring lower working concentrations, prepare further dilutions of the reconstituted stock in culture medium or buffered solutions containing carrier proteins, such as PBS with 0.1% bovine serum albumin. This approach protects the protein from non-specific adsorption to vessel surfaces and maintains biological activity during experimental procedures. References & Citations1. Siren, AL. et al. (2001) Proc Natl Acad Sci USA 98: 4044 2. Haroon, ZA. et al. (2003) Am J Pathol 163: 993 Certificate of AnalysisIMPORTANT Use lot specific datasheet for all technical information pertaining to this recombinant protein. |
Related Products
Prod No. | Description |
|---|---|
E302 | |
E195 | |
E225 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
